Home › Funds › Yorkville Advisors Global, LP › NRSN
Yorkville Advisors Global, LP position in NRSN
NeuroSense Therapeutics Ltd · Health Care
Yorkville Advisors Global, LP reported holding 78,000 shares of NRSN (NeuroSense Therapeutics Ltd) in its Q2 2026 13F filing — a position valued at US$56K, representing 0.07% of its reported portfolio and ranking #34 among its reported holdings. Yorkville Advisors Global, LP has disclosed NRSN holdings in 4 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Yorkville Advisors Global, LP's NRSN position evolved
Yorkville Advisors Global, LP first disclosed a stake in NRSN in Q2 2025 at 60,000 shares (US$113K). Across 4 filings, Yorkville Advisors Global, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 78,000 shares valued at US$56K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 60.00K | $113.40K | New |
| Q4 2025 | 100.00K | $76.90K | New |
| Q1 2026 | 78.00K | $58.89K | Reduce |
| Q2 2026 | 78.00K | $56.16K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NRSN and 13F data
NRSN (NeuroSense Therapeutics Ltd) is a Health Care company. 12 other funds we track also report a position in NRSN. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on Yorkville Advisors Global, LP
FAQ
How long has Yorkville Advisors Global, LP held NRSN?
Yorkville Advisors Global, LP has disclosed NRSN holdings in 4 of the last 5 reported quarters, going back to Q2 2025.
What is Yorkville Advisors Global, LP's current position in NRSN?
As of Q2 2026, Yorkville Advisors Global, LP holds 78.00K shares of NRSN (NeuroSense Therapeutics Ltd), valued at $56.16K, representing 0.07% of its reported portfolio and ranking #34.
Has Yorkville Advisors Global, LP been buying or selling NRSN?
In the latest 13F filing (Q2 2026), Yorkville Advisors Global, LP held unchanged its position in NRSN.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.